Haemophilus influenzae Treatment Guidelines

Introduction to Treatment

• The American Thoracic Society recommends using amoxicillin-clavulanate as first-line therapy for H. influenzae infections because 18-42% of strains produce β-lactamase and are resistant to plain ampicillin or amoxicillin 1, 2

Non-Severe Infections

• For non-severe infections, such as bronchitis, otitis media, sinusitis, and non-severe pneumonia, the preferred oral regimen is amoxicillin-clavulanate 625 mg three times daily, with an alternative option being doxycycline 200 mg loading dose, then 100 mg once daily 3, 4, 1
• For patients with penicillin allergy or intolerance, clarithromycin 500 mg twice daily is a preferred macrolide option due to its better H. influenzae coverage 3, 5, 2
• The treatment duration for non-severe infections is typically 7 days 1, 2

Severe Infections

• For severe infections, such as severe pneumonia, systemic infections, and meningitis, the preferred parenteral regimens include ceftriaxone 1-2 g once to twice daily, cefotaxime 1 g three times daily, and co-amoxiclav 1.2 g three times daily IV 1, 3, 4
• Combination therapy with a β-lactamase stable antibiotic and a macrolide, such as clarithromycin 500 mg twice daily IV, is recommended to cover atypical pathogens and S. aureus 3, 4
• The treatment duration for severe infections is typically 10-14 days, particularly if complications are present 1, 2

Pediatric Considerations

• For children under 12 years, co-amoxiclav is the drug of choice, while doxycycline is an alternative for children over 12 years 5
• For penicillin-allergic children, clarithromycin or cefuroxime are recommended options 5

Critical Decision Point

• The single most important factor in treating H. influenzae infections is whether the strain produces β-lactamase, and β-lactamase-stable agents should be used if the strain is positive or unknown 1, 2

Parenteral-to-Oral Switch

• Patients can be switched to oral therapy when clinical improvement occurs and temperature has been normal for 24 hours, provided there is no contraindication to the oral route 4

Treatment Failure Management

• If there is no improvement after 48-72 hours, the treatment regimen should be switched to a broader-spectrum agent, such as ceftriaxone, and local resistance patterns should be checked 2
• For non-severe pneumonia on combination therapy, changing to a fluoroquinolone with pneumococcal and staphylococcal coverage is recommended 4
• For severe pneumonia not responding to treatment, adding antibiotics effective against MRSA is recommended 4

Common Pitfalls to Avoid

• Plain ampicillin should not be used empirically due to high resistance rates 4
• Antibiotics should not be delayed in severe cases, and should be administered immediately after diagnosis 4
• S. aureus coverage should not be forgotten in influenza-related pneumonia, as co-infection is common 3, 5
• Local resistance patterns should be monitored for fluoroquinolones, as levofloxacin resistance has increased in some regions 2

Treatment of Haemophilus influenzae Infections

Antibiotic Therapy

• The American Academy of Pediatrics recommends amoxicillin 75-100 mg/kg/day divided into 3 doses for β-lactamase negative H. influenzae infections in pediatric patients 6
• The American Academy of Pediatrics recommends amoxicillin-clavulanate with amoxicillin component at 45 mg/kg/day in 3 doses OR 90 mg/kg/day in 2 doses for β-lactamase positive or unknown H. influenzae infections in pediatric patients 7, 6
• The Infectious Diseases Society of America recommends IV ampicillin 150-200 mg/kg/day divided every 6 hours for β-lactamase negative H. influenzae infections in pediatric patients 6
• The Infectious Diseases Society of America recommends ceftriaxone 50-100 mg/kg/day every 12-24 hours OR cefotaxime 150 mg/kg/day every 8 hours for β-lactamase positive or unknown H. influenzae infections in pediatric patients 6
• The American Academy of Pediatrics recommends high-dose amoxicillin-clavulanate (80-90 mg/kg/day of amoxicillin component with 6.4 mg/kg/day clavulanate in 2 divided doses, maximum 2 g per dose) for children <2 years, attending child care, or recent antibiotic use within 30 days 7

Dosing Adjustments

• The Clinical Infectious Diseases journal recommends the following dosing adjustments for amoxicillin-clavulanate in patients with renal impairment: GFR <30 mL/min: Do not use 875 mg/125 mg dose, GFR 10-30 mL/min: 500 mg/125 mg or 250 mg/125 mg every 12 hours, GFR <10 mL/min: 500 mg/125 mg or 250 mg/125 mg every 24 hours, Hemodialysis: 500 mg/125 mg or 250 mg/125 mg every 24 hours, with additional dose during and at end of dialysis 6

Antibiotic Selection and Management for Haemophilus influenzae Infections

Initial Antibiotic Selection

• Plain amoxicillin is recommended when the patient has had no antibiotic exposure in the preceding 4–6 weeks. (Pediatric guideline) 8
• Plain amoxicillin is appropriate for mild disease severity. (Pediatric guideline) 9
• Plain amoxicillin may be used when local prevalence of β‑lactamase‑producing H. influenzae is low. (Pediatric guideline) 10
• Amoxicillin‑clavulanate should be chosen if the patient received antibiotics within the last 4–6 weeks. (Pediatric guideline; American Academy of Otolaryngology‑Head and Neck Surgery) 11
• Amoxicillin‑clavulanate is indicated for moderate to severe disease. (Pediatric guideline; American Academy of Otolaryngology‑Head and Neck Surgery) 11
• Amoxicillin‑clavulanate is advised when the local prevalence of β‑lactamase‑producing strains exceeds 30 %. (Pediatric guideline) 8
• Amoxicillin‑clavulanate should be used after treatment failure on plain amoxicillin. (Pediatric guideline) 9

Dosing Recommendations

• Children: high‑dose amoxicillin 80–90 mg/kg/day divided into 2–3 doses. (Pediatric guideline) 9
• Children: amoxicillin‑clavulanate 90 mg/kg/day amoxicillin component plus 6.4 mg/kg/day clavulanate (14:1 ratio) given in two divided doses. (Pediatric guideline) 9

Resistance Considerations

• Geographic variability exists, with 58–82 % of H. influenzae strains remaining susceptible to amoxicillin. (Pediatric guideline) 9
• High‑dose amoxicillin achieves middle‑ear fluid concentrations above the MIC for most H. influenzae and also covers intermediately resistant Streptococcus pneumoniae. (Pediatric guideline) 9
• Macrolides and trimethoprim‑sulfamethoxazole have bacterial failure rates of 20–25 % against H. influenzae and should be reserved for patients with β‑lactam contraindications. (American Academy of Otolaryngology‑Head and Neck Surgery) 11
• High macrolide resistance rates make macrolides poor first‑line choices. (Pediatric guideline) 8
• Azithromycin should be avoided as first‑line therapy because of inadequate coverage and high resistance. (Pediatric guideline) 10
• Third‑generation oral cephalosporins should not be used as monotherapy when atypical pathogens are suspected, due to insufficient coverage. (Pediatric guideline) 8

Alternative Regimens for Penicillin Allergy

• For non‑type I hypersensitivity, cefdinir 14 mg/kg/day (1–2 doses) is an option. (Pediatric guideline) 9
• For non‑type I hypersensitivity, cefuroxime 30 mg/kg/day (divided twice daily) is an option. (Pediatric guideline) 9
• For non‑type I hypersensitivity, cefpodoxime 10 mg/kg/day (divided twice daily) is an option. (Pediatric guideline) 9
• These cephalosporins have distinct chemical structures with minimal cross‑reactivity risk. (Pediatric guideline) 9
• Cefdinir is preferred based on patient acceptance. (American Academy of Otolaryngology‑Head and Neck Surgery) 11

Monitoring and Treatment Failure

• Reassess clinical response at 48–72 hours; if no improvement, consider escalation. (American Academy of Otolaryngology‑Head and Neck Surgery) 11
• If treatment fails, switch to a broader‑spectrum agent such as ceftriaxone 50 mg/kg/day IM/IV for 3–5 days. (Pediatric guideline; American Academy of Otolaryngology‑Head and Neck Surgery) 11
• Consider tympanocentesis for culture when treatment failure occurs. (Pediatric guideline) 9

Adverse‑Effect Considerations

• The 14:1 amoxicillin‑clavulanate formulation is associated with less diarrhea than other ratios. (Pediatric guideline) 9